In general, [177Lu]Lu-PSMA-617 showed optimal key parameters for therapeutic radiopharmaceutical development, such as stronger PSMA binding affinity, more internalization, higher tumor-to-background contrast at late time points, and faster kidney clearance than [68Ga]Ga-PSMA-11. This evidence concerns the gene FOLH1 and neoplasm.